1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AA770395EB421D910025878B005BBBCC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/AA770395EB421D910025878B005BBBCC?OpenDocument
18
19OpenDocument
2023.20.20.52
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Education

Document Excerpt: How Pharma is Utilizing IME Grants for Patient Education and Medical Sponsorships

DB Image

ID: MD-806


Features:

15 Info Graphics

20 Data Graphics

120 Metrics

5 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".


To return to the study abstract to purchase the full study - click here.

This excerpt includes research findings and metrics from document #5706 "How Pharma is Utilizing IME Grants for Patient Education and Medical Sponsorships"

Industries Profiled:
Pharmaceutical; Health Care; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Biopharmaceutical


Companies Profiled:
AbbVie; Merck; Astellas; Merck Serono; Bayer; Eisai; Teva Pharmaceutical Industries Ltd; Roche; GlaxoSmithKline ; AstraZeneca; Biogen; bioMerieux; Allergan; Sanofi Genzyme; Otsuka Pharmaceutical Development & Commercialization; Inc. (OPDC); Sandoz; Baxter BioScience; Ipsen; Merz Pharma; MEDiSTRAVA; Kyowa Kirin; CSL Behring; Grunethal; GRAIL; Apellis Pharmaceuticals; Rhythm Pharmaceuticals; Taiho Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.